In this study, subjects were randomized to either nicotine replacement patches or ENDS devices using e-nicotine liquid cartridges. In order to maintain the blind, subjects used both the nicotine replacement patches and the ENDS devices. Subjects were requested not to smoke, but the number of regular cigarettes used were collected. Subject were seen every day for 15 days. The nicotine patch was applied, at rotating sites, and the nicotine cartridge was replaced every day. The cartridge was weighed when dispensed and upon return. On days, 1, 5, and 10. subjects remained in the clinic for 4 hours for collection of biomarkers. On these days, a new ENDS nicotine cartridge was inserted and 10 puffs were taken over 10 minutes, and not used for the remaining collection period. A new cartridge was inserted at the end of the 4 hour collection period. A nicotine replacement patch was applied prior to using the ENDS device on these days.
The SU domain was used to represent the number of cigarettes used, but is not shown.
In this study, the weight of the contents in the cartridge was tracked. A Product Accountability (DA) domain was submitted to represent dispensed and returned weights of each cartridge. Only a few rows are shown. The produt accountability information was not provided for the nicotine replaement patches.
da.xpt
xx.xpt
Row
STUDYID
DOMAIN
USUBJID
DASEQ
DAREFID
DATESTCD
DATEST
DACAT
DASCAT
DAORRES
DAORRESU
DASTRESC
DASTRESN
DASTRESU
VISITNUM
DADTC
1
TEDP07
DA
10001
1
CRT8754
DISPAMT
Dispensed Amount
STUDY PRODUCT
E-LIQUID
25.3
g
25
25
g
1
2004-06-06
2
TEDP07
DA
10001
2
CRT8754
RETAMT
Returned Amount
STUDY PRODUCT
E-LIQUID
23
g
23
23
g
1
2020-06-06
3
TEDP07
DA
10001
3
CRT9756
DISPAMT
Dispensed Amount
STUDY PRODUCT
E-LIQUID
25.1
g
25
25
g
1
2020-06-07
4
TEDP07
DA
10001
4
CRT9756
RETAMT
Returned Amount
STUDY PRODUCT
E-LIQUID
10
g
14
14
g
2
2020-06-08
5
TEDP07
DA
10001
5
CRT9955
DISPAMT
Dispensed Amount
STUDY PRODUCT
E-LIQUID
25.2
g
25
25
g
2
2004-06-08
$warningHtml
EC was used to represent the collected exposure data since a double dummy design was used. The EX domain was used to represent the subject's exposure to the actual product containing nicotine. The sponsor represented each cartridge and patch used. The dose was represented as "1" to indicate one cartidge or patch. The actual date and specific time of usage of the cartridge was recorded on days 1, 5, and 10, while only the date of usage was reccorded on other days.
$titleHtml
ec.xpt
Row
STUDYID
DOMAIN
USUBJID
ECSEQ
ECTRT
ECDOSE
ECDOSTXT
ECDOSU
ECDOSFRM
ECROUTE
ECLOC
ECLAT
ECDIR
EPOCH
ECSTDTC
ECENDTC
1
TEDP07
EC
10001
1
ENDS
10
PUFF
CARTRIDGE
RESPIRATORY (INHALATION)
PRODUCT EXPOSURE
2020-06-01T08:00
2020-06-01T08:10
2
TEDP07
EC
10001
2
PATCH
1
PATCH
PATCH
TRANSDERMAL
ARM
RIGHT
UPPER
PRODUCT EXPOSURE
2020-06-01
2020-06-02
3
TEDP07
EC
10001
3
ENDS
AD LIBITUM
PUFF
CARTRIDGE
RESPIRATORY (INHALATION)
PRODUCT EXPOSURE
2020-06-01T12:10
2020-06-02
4
TEDP07
EC
10001
4
ENDS
AD LIBITUM
PUFF
CARTRIDGE
RESPIRATORY (INHALATION)
PRODUCT EXPOSURE
2020-06-02
2020-06-03
5
TEDP07
EC
10001
5
PATCH
1
PATCH
PATCH
TRANSDERMAL
ARM
LEFT
UPPER
PRODUCT EXPOSURE
2020-06-02
2020-06-03
6
TEDP07
EC
10001
6
ENDS
AD LIBITUM
PUFF
CARTRIDGE
RESPIRATORY (INHALATION)
PRODUCT EXPOSURE
2020-06-03
2020-06-04
7
TEDP07
EC
10001
7
PATCH
1
PATCH
PATCH
TRANSDERMAL
LEG
LEFT
UPPER
PRODUCT EXPOSURE
2020-06-03
2020-06-04
7
TEDP07
EC
10001
8
ENDS
AD LIBITUM
PUFF
CARTRIDGE
RESPIRATORY (INHALATION)
PRODUCT EXPOSURE
2020-06-04
2020-06-05
8
TEDP07
EC
10001
9
PATCH
1
PATCH
PATCH
TRANSDERMAL
LEG
LEFT
LOWER
PRODUCT EXPOSURE
2020-06-04
2020-06-05
9
TEDP07
EC
10001
10
ENDS
10
PUFF
CARTRIDGE
RESPIRATORY (INHALATION)
PRODUCT EXPOSURE
2020-06-10T8:30
2020-06-10T8:40
10
TEDP07
EC
10001
11
PATCH
1
PATCH
PATCH
TRANSDERMAL
LEG
RIGHT
LOWER
PRODUCT EXPOSURE
2020-06-10
2020-06-11
11
TEDP07
EC
10001
12
ENDS
AD LIBITUM
PUFF
CARTRIDGE
RESPIRATORY (INHALATION)
PRODUCT EXPOSURE
2020-06-10T12:40
2020-06-11
$warningHtml
Subject 10001 was randomized to the 5% pharmaceutical strength of the e- nicotine liquid, and subject 20001 was randomized to the nicotine patch with a pharmaceutical strength of 14mg. The sponsor only represented the active product exposure for each subject in EX. Note, only repreesentive rows are included.